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Ramipril prolongs life and is cost effective in chronic protein- [1]. About 400 subjects per million population in Europe,
uric nephropathies. 800 in Japan, and 1000 in the United States are currently
Background. Our objectives were to predict the long-term on chronic renal replacement therapy. These figures willcost and efficacy of the angiotensin-converting enzyme, rami-
progressively increase worldwide because of the growingpril, in patients with nondiabetic chronic nephropathies.
number of diabetics and hypertensives in the next decadeMethods. The time to end-stage renal disease (ESRD) was
predicted by two different models based on the rate of glomeru- as well as better healthcare facilities that already allow
lar filtration rate decline (DGFR) and incidence of ESRD more renal patients to live long enough to progress to
(events) measured during the Ramipril Efficacy in Nephropa- ESRD [2]. Thus, in 1995 in the United States, more thanthy Trial in 117 and 166 patients, respectively, randomized to
200,000 patients were on chronic dialysis, and 70,000 hadcomparable blood pressure control with ramipril or conven-
a functioning kidney graft [1]. With the prevalence oftional therapy. Direct medical costs of conservative and renal
replacement therapy were estimated by a payer perspective, ESRD growing by 7 to 9% per year, it could be expected
and cases more and less favorable to ramipril were computed that more than 350,000 patients will require chronic renal
by a sensitivity analysis. The study took place at the Clinical replacement therapy by the year 2010 [3].Research Center for Rare Diseases, “Aldo & Cele Dacco`,”
The cost of these treatments is now and will increas-Bergamo, Italy. Patients included those with chronic, nondia-
ingly be a major public health concern in the future. Inbetic nephropathies and persistent urinary protein excretion
rate $3 g/24 h. Time to ESRD, survival, and direct costs of Western countries, expenses for chronic renal replace-
conservative and renal replacement therapy are discussed. ment therapy average $45,000 per-patient/year [1, 4].
Results. Both in the DGFR-based or events-based models,
Inpatient and outpatient expenditures for ESRD, includ-ramipril delayed progression to ESRD and prolonged patient
ing hemodialysis, peritoneal dialysis, and transplanta-survival by 1.5 to 2.2 and 1.2 to 1.4 years, respectively, and
saved $16,605 to $23,894 lifetime and $2,422 to $4203 yearly tion, in 1995 totaled $13.1 billion in United States, $9
direct costs per patient. Even in the less favorable hypotheses, billion in Europe, and $7 billion in Japan. More impor-
ramipril allowed lifetime and yearly cost savings that exceeded tant, in the same countries, the total life expectancy for
10 to 11 and 20 to 40 times, respectively, the additional costs
adults with ESRD is still less than a decade, which isrelated to prolonged survival.
similar to that of certain cancers, and the overall mortal-Conclusions. In our study population, ramipril prolongs life
while saving money because of its beneficial effect on the course ity rate in some countries approaches 25% per year [4].
of nondiabetic chronic nephropathies. These considerations indicate that efforts to delay the
progression of chronic renal disease to ESRD are crucial
for nephrologists in order to prolong their patients’ sur-
End-stage renal disease (ESRD) extracts a high toll vival and ameliorate their quality of life, while at the
in terms of the patient’s reduced life expectancy, quality same time they must reduce the current and future renal
of life, and consumption of overall health care resources care budget, which soon will become an unbearable bur-
den for most countries. Previous data found that in type
1 diabetic nephropathy, the angiotensin-converting en-Key words: end-stage renal disease, renal replacement therapy, hyper-
tension, progression of kidney disease. zyme (ACE) inhibitor captopril, by delaying progression
to ESRD, was remarkably life prolonging and cost effec-Received for publication September 10, 1999
tive [5]. After documenting that chronic treatment withand in revised form June 13, 2000
Accepted for publication July 26, 2000 the ACE inhibitor ramipril was indeed nephroprotective
in patients with proteinuric chronic nephropathies of theÓ 2001 by the International Society of Nephrology
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Fig. 1. Expected course of disease in patients with chronic proteinuric nephropathies according to ramipril or conventional plus non-angiotensin-
converting enzyme (ACE) inhibitor therapy. Simulated in a Marcow model, we used the number of cohort members in any given state of health
and the probability of transition to each other state. The rectangles represent the different states of health, and the arrows represent the possible
transition between the different states. Arrows from a rectangle circling back upon the same rectangle indicate that a patient can remain in that
state until he or she eventually dies. Note that patients may die of any cause related or unrelated to renal disease either on conservative treatment
or on renal replacement therapy.
nondiabetic type [6], our current study extended these mL/min/1.73 m2. Time to ESRD is defined as the time
required for each individual to reach a GFR 5 10/mL/data and applied a model that could predict the long-
term cost and effectiveness profiles of ramipril therapy min/1.73 m2 on the basis of his or her own baseline GFRs
and predicted follow-up DGFRs.in this category of patients.
(2) Events-based model. The incidence of ESRD pre-
dicted in the two groups over the patients’ lifetime is
METHODS
equal to the average incidence effectively measured dur-
The model ing the trial.
Only patients with at least three measures of GFR (in-A medical treatment model was developed to estimate
the cost and effectiveness profiles of ramipril given to cluding baseline) to calculate the DGFR were considered
in the DGFR-based model [6]. Both models considereddelay the progression of the disease to ESRD or death
in chronic, proteinuric nephropathies [7, 8]. The model the possibility for patients to die either before or after
progression to ESRD. Since only three deaths occurredcaptured the events occurring over the patient’s pre-
dicted lifetime (either before and after progression to during the trial, the pre- and post-ESRD mortality rate
was predicted by data derived from comparable seriesESRD) from the time of randomization into two groups
with comparable values of blood pressure control: those of patients [9–11]. Conservatively, antihypertensive ther-
apy with or without ACE inhibitors was considered towho did (ramipril group) or did not (control group) re-
ceive ACE inhibition therapy (Fig. 1). Data from the have a comparable effect on the overall cardiovascular
morbidity and mortality rate, even if the available dataREIN study on those patients who, in addition to the
actual incidence of ESRD, had their rate of progression suggested a specific cardioprotective and lifesaving po-
tential of ACE inhibitors in patients with nondiabeticof the disease precisely evaluated by repeated measures
of true GFR [6] allowed us to predict progression to chronic nephropathies, especially after progression to
ESRD [12, 13].ESRD in the two treatment groups. Two different mod-
els based on the following assumptions were used: On the basis of the previously mentioned assumptions,
both models allowed a prediction of the percentage of(1) Glomerular filtration rate of decline (DGFR) mod-
el. The DGFR predicted in the two groups over the patients in the two treatment groups who at each time
point after completion of the REIN trial were still onpatients’ lifetime is equal to the DGFR effectively mea-
sured during the trial. ESRD is defined as GFR 5 10/ conservative treatment, had progressed to ESRD, or had
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died [6]. These parameters were estimated until the last a multiple-state, long-term decision analytical model,
patient in each treatment group was predicted to die. constructed using the Excel 7.0 Spreadsheet (Microsoft,
This permitted a calculation of the total patient-years Seattle, WA, USA). A sensitivity analysis was used to
spent in both treatment groups on conservative treat- compute the best case and worst case results, that is, the
ment or on renal replacement therapy. conditions that were most favorable (lowest costs and
highest health benefits) or less favorable (highest costs
Estimation of costs and lowest health benefits) to ramipril, as compared with
For the analysis of cost-effectiveness, a payer perspec- non-ACE inhibitor therapy. The best and worst cases
tive was adopted [14]. All of the direct medical costs were estimated varying the key variables of the model
were considered, including those for out-patient and in- (that is, pre- and post-ESRD costs and mortality rate)
patient care, medications, medical equipment, supplies, by 610% and the discount rate by 62%. Thus, according
and laboratory tests. Costs for patient management be- to the analysis of extremes, for both models we consid-
fore progression to ESRD were extrapolated from the ered only the most positive and most negative results.
direct costs of patients on ramipril or placebo plus con- Robustness of results was further assessed by evaluating
ventional therapy during the REIN trial [6]. Public prices the consistency of the data derived from the two models.
were considered to calculate the expense of medications. Data were analyzed on an intention-to-treat basis by
The costs of the tests specifically performed for the pur- SAS software (release 6.12). Dichotomous and polychot-
poses of the REIN trial, but not routinely used in clinical omous baseline characteristics were compared by use of
practice (that is, GFR measurement), were not consid- Fisher’s exact test and continuous baseline characteris-
ered. The costs of chronic renal replacement therapy by tics by use of Wilcoxon rank-sum test. Comparisons be-
hemodialysis, peritoneal dialysis, or kidney transplanta- tween outcome variables were done by the unpaired
tion were estimated on the basis of previously published t test. A P value under 0.05 was taken to indicate signifi-
data [15–18]. Average yearly costs of conservative treat- cance.
ment or renal replacement therapy (by hemodialysis,
peritoneal dialysis, or kidney transplant) were then cal-
culated. Total lifetime costs for management of all pa- RESULTS
tients in both groups were then calculated by multiplying Baseline characteristics of the 117 patients with mea-
the yearly costs for the total patient-years predicted (by surable DGFRs included in the DGFR-based model are
the DGFR-based or the events-based model) to be spent given in Table 1; those of all of the 166 Stratum 2 patients
on conservative or renal replacement therapy, respec- of the REIN study included in the events-based model
tively. Lifetime single-patient costs were then calculated have been described elsewhere [6]. Of note, in both mod-
by dividing total costs for the number of patients in each els, baseline characteristics of patients randomized to
treatment group. Correction of such costs for the average ramipril or conventional therapy (control group) were
survival predicted for patients of both groups allowed comparable.
an estimation of the individual yearly costs. Finally, sepa-
rately considering the lifetime spent on conservative Renal and patient outcome
treatment or on renal replacement therapy allowed the
Time to ESRD (Figs. 2 and 3) and overall patientcalculation of individual treatment costs before and after
survival (Fig. 3) predicted by DGFR-based and events-progression to terminal renal failure, respectively.
based models in the two treatment groups were remark-Both cost and efficacy were discounted at 5% per
ably consistent. Both models predicted a reduced andannum to reflect the fact that, in general, individuals and
delayed progression to ESRD and a prolonged patientsociety have a positive rate of time preference [14]. This
survival in the ramipril as compared with the controlis because individuals would prefer to achieve an ex-
group, and the difference in time to ESRD between thepected benefit, even if it is only a partial benefit, when
two treatment groups was highly significant in the events-it is immediate (immediate gratification), rather than
based model (Fig. 3). As a consequence of the longerachieve a full benefit in an uncertain future (delayed
survival on conservative treatment, at the time of pro-gratification). The discount rate accounts for this kind
gression to ESRD, ramipril patients were older as com-of preference [19].
pared with controls (mean age 6 SD; DGFR model, 56.5 6
Data analyses 1.0 vs. 55.0 6 0.9, P 5 0.19; events model, 56.9 6 1.1 vs.
54.7 6 0.9, P , 0.01), and therefore had a shorter lifeUsing the medical event rates and the costs associated
expectancy while on chronic replacement therapy (Fig. 3).with each event, both the DGFR-based and the events-
The net effect of longer pre-ESRD and a shorter on-based model allowed a prediction of the costs incurred
ESRD survival was a longer overall survival for patientsover a lifetime in a cohort of patients treated with or
without ACE inhibitors. The form of both models was on ramipril treatment as compared with controls (Fig. 3).
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Table 1. Clinical characteristics at the time of randomization of patients with chronic nephropathy, baseline urinary protein
excretion rate $3 g/day and with at least 3 GFR measurements, who were randomized to ramipril or placebo and were
considered in the DGFR based modela
Variable Ramipril (N 5 56) Placebo (N 5 61) P valueb
Demographics
Age years 46.2613.2 49.5613.1 0.21
Male 47 (84%) 44 (72%) 0.12
Female 9 (16%) 17 (28%)
Renal disease
Glomerular 38 (68%) 38 (62%) 0.58
Interstitial, polycystic 2 (3%) 5 (8%)
Other, unknown 16 (29%) 18 (30%)
Renal function
GFR mL/min/1.73 m2 39.4617.5 38.9617.2 0.93
Creatinine clearance mL/min/1.73 m2 47.9622.7 44.6620.8 0.40
Serum creatinine mmol/L 207691 204673 0.87
Urinary protein excretionc g/24 day 5.763.0 5.061.9 0.33
Urinary urea nitrogen excretion g/day 341.36170.0 307.56145.6 0.27
Urinary sodium excretion mEq/day 196.06101.2 210.46171.3 0.84
Arterial blood pressure
Systolic mm Hg 145.5615.8 146.2616.6 0.97
Diastolic mm Hg 90.6611.2 89.469.9 0.63
Mean mm Hg 108.9611.1 108.3610.2 0.84
Number of patients with hypertensiond
All with hypertension 48 (86%) 57 (93%) 0.23
On hypertensive therapy 40 (71%) 48 (79%) 0.40
Lipids and potassium
Serum cholesterol mmol/L 6.7162.34 6.7161.52 0.42
Serum tryglycerides mmol/L 2.4662.05 2.4361.40 0.53
Serum potassium mmol/L 4.3760.52 4.4560.62 0.23
a Plus-minus values are means 6 SD. To convert values for serum creatinine to mg/dL, divide by 88.4. To convert values for urinary urea nitrogen to g/day, divide
by 16.65. To convert values for serum cholesterol and tryglycerides to mg/dL, divide by 0.02586 and by 0.01129, respectively
b For categorical variables, the P values were based on Fisher’s exact test, for continuous variables on Wilcoxon test, and for “Sex” on Chi-square test
c Urinary protein excretion is the mean of the last two measurements before randomization
d Patients who had sitting systolic or diastolic blood pressure above 140/90 mm Hg or were receiving antihypertensive therapy were considered to have hypertension
Costs tients as compared with controls. As a consequence, ei-
ther lifetime and per-patient/year treatment costs wereThe treatment costs for the ramipril and control
remarkably lower for the patients on ramipril therapygroups estimated by the DGFR-based and the events-
as compared with controls (Table 2).based models are summarized in Table 2. Lifetime treat-
Both the DGFR-based and the events-based modelsment costs before progression to ESRD were higher
consistently found that the costs saved in the ramiprilin ramipril-treated patients as compared with controls.
group because of reduced and delayed progression toMost of the difference, however, was accounted for by
ESRD largely exceeded the costs for the consumptionthe prolonged survival of patients on ramipril therapy
of the study drug (Table 2). Thus, both models foundbefore progressing to ESRD, which in turn accounted for
that ramipril therapy allowed lifetime and per-patient/a higher consumption of drugs before renal replacement
year cost savings that exceeded by 10 to 11 times andtherapy was started. Actually, when per-patient/year
20 to 40 times the additional costs related to drug con-treatment costs were considered, only marginal differ-
sumption, respectively (Table 2). Of note, per-patient/ences between the two treatment groups were demon-
year costs predicted over a patient’s lifetime by thestrated that were accounted for by the expenses for the
DGFR-based model (ramipril, $7313; placebo, $9735)study drug in ramipril-treated patients that were only in
were almost superimposable to the actual per-patient/part counterbalanced by more expenses for other antihy-
year costs (ramipril, $7313; placebo, $9944) effectivelypertensives in controls. Costs for other concomitant
measured during the REIN Core [6] and follow-up [28, 29]treatments, laboratory tests, and visits were comparable
studies.in the two groups.
Lifetime treatment costs after progression to ESRD
Sensitivity analysiswere lower for patients on ramipril therapy as compared
Results of the sensitivity analyses are given in Figureswith controls (Table 2). The difference was accounted
4 and 5. Both the DGFR-based and events-based modelsfor by the reduced number of patients progressing to
found that, even in the less favorable hypotheses, rami-ESRD and by the shorter period of time spent on chronic
renal replacement treatment for the ramipril-treated pa- pril as compared with non-ACE inhibitor treatment in-
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Fig. 3. Time on conservative therapy (pre-ESRD) or chronic renal
replacement therapy (with ESRD), and overall survival rate predicted
by the DGFR-based and the events-based models. Symbols are: ( )
ramipril; ( ) placebo plus non-ACE inhibitor. Data are mean 6 SEM.
Fig. 2. Number of patients predicted to progress to end-stage renal
disease (ESRD) by the DGFR-based model (A) and the events-based
(B) models at different times after completion of the REIN study.
Symbols are: (j) ramipril; (h) placebo plus non-ACE inhibitor. pressure control during the REIN study accounted for
the different outcome predicted by the two models for
patients on ramipril as compared with controls. In partic-
ular, baseline blood pressure, 24-hour protein excretioncreased life expectancy by prolonging pre-ESRD sur-
rate, GFR, and distribution of primary glomerular andvival, and it decreased direct costs by reducing the
nonglomerular diseases were comparable in the twoproportion of lifetime spent on chronic renal replace-
groups, which renders it unlikely that the different out-ment therapy. As a consequence, even in the less favor-
comes were actually dependent on different underlyingable hypotheses, both the DGFR-based and the events-
renal diseases, rather than on the treatment under evalu-based model predicted an overall per patient lifetime
ation.and per year cost saving ranging from $6650 to $13,324
Here we had the unique opportunity to predict pro-(Fig. 4) and from $936 to $2276 (Fig. 5), respectively.
gression to ESRD by two approaches based on individual
GFR slopes and on the incidence of events measured in
DISCUSSION the two treatment groups while on the REIN study [6],
and to compare the results for consistency. Actually, theIn the present study, ramipril therapy was predicted
previously mentioned study was the only large-scale trialto delay the progression to ESRD, prolong survival, and
on ACE inhibitors in chronic nephropathies that evalu-decrease the treatment costs in patients with nondiabetic,
ated disease progression by repeated measures of truechronic, proteinuric nephropathies.
Neither biases in patients’ randomization or in blood GFR. This allowed the prediction of renal outcome by
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Table 2. Patient lifetime and per year costs ($) in the ramipril and in the placebo group before progression to ESRD, during chronic renal
replacement therapy, and overall predicted by the DGFR-based and events-based models
DGFR-based model Events-based model
Pre-ESRD On ESRD Overall Pre-ESRD On ESRD Overall
Lifetime costs
Ramipril 5,715 79,185 84,900 5,704 76,145 81,849
Placebo 4,048 97,456 101,505 3,559 102,145 105,723
D(Ramipril 2 Placebo) 11,667 218,271 216,605 12,145 226,000 223,894
Per year costs
Ramipril 1,112 20,771 7,313 919 21,587 8,540
Placebo 999 24,039 9,735 814 26,049 12,743
D(Ramipril 2 Placebo) 1113 23,268 22,422 1105 24,462 24,203
D(Ramipril 2 Placebo) indicates the differences in treatment costs between the two groups.
Fig. 4. Analysis of extremes (worst case vs. best case) of per patient lifetime costs saved by ramipril versus placebo plus non-ACE inhibitor
antihypertensive agents using the DGFR-based (A) and the events-based (B) models. Despite a slight excess in the costs for conservative therapy
before progression to end stage renal disease (pre-ESRD), both models predicted a remarkable reduction in per patient lifetime overall costs for
ramipril as compared with placebo plus non-ACE inhibitor antihypertensive agents, because of the large reduction in costs for chronic renal
replacement therapy (with ESRD). The reduction in overall costs was still evident in both models even when the worst case for ramipril was
considered.
a DGFR-based model considering a GFR cut-off value data interpretation. On the other hand, to date GFR is
the best indicator of renal function, and DGFR—being(that is, GFR 5 10 mL/min/1.73 m2) to define ESRD.
Other clinical and laboratory parameters that may con- constant over time [6, 20]—can indeed be used as a
reliable indicator of the rate of disease progression [21].tribute towards establishing a diagnosis of ESRD, such
as azotemia, fluid overload, anemia, and many others, The REIN study was also the only trial on ACE inhibi-
tors with a consistent number of hard end points (thatwere not considered in our analysis, because they were
dependent upon individual clinical judgment, which is, progression to ESRD) in this population of patients.
This permitted the use of an events-based model, whichmade it difficult to standardize and may have confounded
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Fig. 5. Analysis of extremes (worst case vs. best case) of per-patient/year costs saved by ramipril versus placebo plus non-ACE inhibitor
antihypertensive agents using the DGFR-based (A) and the events-based (B) models. Predicted costs for conservative therapy before progression
to end-stage renal disease (pre-ESRD) were comparable. Thus, because of the large reduction in costs for chronic renal replacement therapy (with
ESRD), both models predicted a remarkable reduction in per-patient/year overall costs for ramipril as compared to placebo plus non-ACE inhibitor
antihypertensive agents. The reduction in overall costs was still evident in both models even when the worst case for ramipril was considered.
assumed the incidence of “true” events averaged during duced and delayed progression to ESRD actually ac-
counted for the cost-saving effect with ramipril treat-the REIN study to be constant over time, to predict
kidney outcome over a lifetime period in the two groups ment. Actually, both the DGFR-based and the events-
based models predicted that ramipril prolonged meanof patients achieving a comparable level of blood pres-
sure control with or without ACE inhibitor therapy. patient survival by more than one year and in parallel
reduced patient/year costs by $2000 to $4000, respec-Both models predicted a reduced and delayed progres-
sion to ESRD, which in turn accounted for an increased tively. The reliability of this estimate was further corrobo-
rated by the finding that ramipril-associated per-patient/proportion of the patients’ lifetime spent on conservative
therapy and a parallel decrease in the proportion spent year cost savings predicted by the DGFR-based model
over a patient’s lifetime (that is, $2422) were virtuallyon chronic renal replacement therapy. Because the pre-
ESRD mortality rate was about tenfold lower than that superimposable to the true cost savings measured during
the REIN Core [6] and follow-up [28, 29] studies (thatfor post-ESRD [9–11], the reduced and delayed progres-
sion to ESRD eventually accounted for the prolonged is, $2631). Ramipril retained a clear life-saving and cost-
saving potential even when the less favorable hypothesespatient survival. Note that this was a conservative predic-
tion since our model did not consider the specific cardio- were considered with a sensitivity analysis. This com-
bined with the strong consistency of the results achievedprotective and lifesaving potential of ACE inhibitors
suggested by recent studies in patients with nondiabetic by the two models provides further evidence of the relia-
bility of our findings. The cost-effectiveness of ramiprilchronic nephropathies who were on renal replacement
therapy [12, 13]. Along this same line, with the costs of therapy would be even greater if quality-adjusted-life-
years and indirect costs were included in the analysis.conservative treatment being 20- to 40-fold lower than
the costs of chronic renal replacement therapy, the re- Both the GFR-based and the events-based models
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